BioCanada

Found 35,597 articles

• Boehringer Ingelheim Canada and community-based clinics join to revolutionize cardiovascular care in Ontario

  12/7/2023

  In an innovative partnership, Boehringer Ingelheim Ltd. has joined forces with established cardiology clinics across Ontario to transform community care for cardiovascular patients through a cardiovascular optimization program, emphasizing accessibility and collaboration.

• Microbix & BioGX Collaborate on real-time PCR Assays & Controls

  12/7/2023

  Microbix Biosystems Inc., a life sciences innovator, manufacturer, and exporter, announces a collaboration with BioGX, Inc., a global provider of easy molecular diagnostic solutions.

• Oncolytics Biotech® and SOLTI Present Positive Translational Data at SABCS

  12/7/2023

  Oncolytics Biotech® Inc. (NASDAQ: ONCY) (TSX: ONC), a clinical-stage immunotherapeutics company focused on oncology, today announced the presentation of additional translational data from the AWARE-1 breast cancer window-of-opportunity study conducted in combination with SOLTI-Innovative Cancer Research at The San Antonio Breast Cancer Symposium (SABCS).

• Alpha Cognition Announces FDA Acceptance of New Drug Application for ALPHA-1062 for Mild-to-Moderate Alzheimer’s Disease

  12/7/2023

  Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (Alpha Cognition “ACI”, or the “Company”) is pleased to announce that the U.S. Food and Drug Administration (FDA) has completed its filing review and has accepted the company’s New Drug Application (NDA) for ALPHA-1062, a proprietary, patented, delayed release oral tablet formulation in development for the treatment of mild-to-moderate Alzheimer’s Disease.

• Justera Announces 2023 AGM Results

  12/7/2023

  Justera Health Ltd. (CSE: VTAL) (OTC Pink: SCRSF) ("Justera" or the "Company") announces the voting results from the Annual General and Special Meeting of Shareholders (the "Meeting") which was held on December 6, 2023.

• Lexaria's Investigational New Drug Application Filing Update

  12/7/2023

  Lexaria Bioscience Corp. announces that the Company's anticipated submission of an Investigational New Drug application with the U.S. Food and Drug Administration for its planned U.S. Phase 1b Hypertension Clinical Trial is expected to be filed within approximately 45 days.

• IPA Announces Pricing of $1.1 Million Public Offering of Common Shares

  12/6/2023

  ImmunoPrecise Antibodies Ltd. announced that it has priced its underwritten public offering of 1,100,000 common shares at a public offering price of $1.00 per share.

• Microbix Announces Initiation of Normal Course Issuer Bid

  12/6/2023

  Microbix Biosystems Inc. announces the initiation of a Normal Course Issuer Bid program for the repurchase and cancellation of outstanding common shares.

• BriaCell Highlights Outstanding Topline Survival and Clinical Benefit Data in Advanced Metastatic Breast Cancer at the 2023 SABCS

  12/6/2023

  BriaCell Therapeutics Corp. is thrilled to announce continued outstanding topline survival and clinical benefit data in advanced metastatic breast cancer patients treated Bria-IMT™ in combination with an immune check point inhibitor (CPI).

• Medical Technology Innovator Thornhill Medical’s MOVES® SLC™ is acquired for United States Marine Corp En Route Care Modernization and added to Authorized Medical Allowance List (AMAL) 647

  12/6/2023

  Medical technology innovator Thornhill Medical is pleased to announce that the United States Marine Corps (USMC) has acquired its integrated life support technology, MOVES® SLC™.

• Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Deuterated Psilocybin Analog Program

  12/6/2023

  Cybin Inc. today announced that the United States Patent and Trademark Office (“USPTO”) has granted U.S. patent 11,834,410 in support of its CYB003 program.

• Telo Genomics Gears up for American Society of Hematology Conference

  12/6/2023

  Telo Genomics Corp. (TSXV: TELO) (OTCQB: TDSGF) (FSE: 3DOA), (the "Company" or "Telo"), an emerging molecular testing platform provider leveraging the power of telomeres, looks forward to attending the American Society of Hematology (ASH) annual meeting in San Diego this week.

• Treadwell Announces Strategic Pipeline Prioritization and Leadership Transitions

  12/6/2023

  Treadwell Therapeutics today announced that it is realigning its pipeline, workforce and management structure to support its highest value program and extend its cash runway to prioritize the execution of key near term value drivers and clinical milestones.

• BriaCell 2023 SABCS Posters Confirm Activation of Cancer-Fighting Immune Cells and Identify Potential Predictors of Clinical Benefit

  12/6/2023

  BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is presenting 3 posters including two today at the 2023 San Antonio Breast Cancer Symposium® at Henry B. Gonzalez Convention Center, San Antonio, TX.

• IntelGenx Announces Closing of Previously Announced Subsequent Non-Brokered Private Placement With atai Life Sciences for Aggregate Gross Proceeds of US$750,000

  12/5/2023

  IntelGenx Technologies Corp. announces the closing of the previously announced subsequent non-brokered private placement of 750 units with atai Life Sciences AG for aggregate gross proceeds of US$750,000, on the same terms as the August 31, 2023, offering of units, following the Shareholder Approvals obtained at the special meeting held on November 28, 2023.

• ZYUS Life Sciences Corporation Announces Phase 2 Clinical Trial Evaluating Trichomylin® Softgel Capsules for Advanced Cancer Pain Management

  12/5/2023

  ZYUS Life Sciences Corporation announced today it has made the strategic decision to proceed with a Phase 2 Clinical Trial in Canada to assess the preliminary efficacy, safety and tolerability of Trichomylin® softgel capsules in patients with advanced cancer and moderate to severe cancer-related pain.

• Medicure Announces New Partnership Through Its Marley Drug Subsidiary to Provide Brenzavvy(R) as an Affordable Medication for Americans with Type 2 Diabetes

  12/5/2023

  Medicure Inc. through its pharmacy subsidiary Marley Drug®, a trusted national pharmacy known for its commitment to affordable healthcare solutions, is pleased to announce a partnership with TheracosBio to distribute a newly approved diabetes drug, BRENZAVVY® tablets, a sodium-glucose cotransporter-2 inhibitor, at an affordable cash price delivered directly to patient homes in all 50 US states and territories.

• IPA Announces Proposed Public Offering of Common Shares - December 05, 2023

  12/5/2023

  ImmunoPrecise Antibodies Ltd., announced that it intends to offer and sell common shares in an underwritten public offering.

• ABK Biomedical announces that its Eye90 microspheres device has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA)

  12/5/2023

  ABK Biomedical, Inc. announces its Eye90 microspheres device has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). 

• Mark Vineis appointed as the new Country President of Novartis Canada

  12/5/2023

  Novartis Canada announces that Mark Vineis has been appointed to the role of Country President, effective as of January 1, 2024.